about
Serology-enabled discovery of genetically diverse hepaciviruses in a new hostIdentification of rodent homologs of hepatitis C virus and pegivirusesStructures of hepatitis C virus nonstructural proteins required for replicase assembly and functionHCV-Mediated Apoptosis of Hepatocytes in Culture and Viral PathogenesisA combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decayElucidation of hepatitis C virus transmission and early diversification by single genome sequencingSensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosidesHCV core residues critical for infectivity are also involved in core-NS5A complex formationCanine hepacivirus is not associated with chronic liver disease in dogs.Visualizing hepatitis C virus infection in humanized mice.A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses.Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.Supporting Role for GTPase Rab27a in Hepatitis C Virus RNA Replication through a Novel miR-122-Mediated EffectSurvival of Hepatitis C Virus in Syringes Is Dependent on the Design of the Syringe-Needle and Dead Space Volume.RNA-sequencing analysis of 5' capped RNAs identifies many new differentially expressed genes in acute hepatitis C virus infectionIdentification and analysis of inhibitors targeting the hepatitis C virus NS3 helicaseFluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.Study of hepatitis C virus entry in genetically humanized miceAffinity Purification of the Hepatitis C Virus Replicase Identifies Valosin-Containing Protein, a Member of the ATPases Associated with Diverse Cellular Activities Family, as an Active Virus Replication Modulator.The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.HCV core protein and virus assembly: what we know without structures.Hepatitis C virus vaccines in the era of new direct-acting antivirals.Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus.Experimental models of hepatitis B and C - new insights and progressCooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity.Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies.Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.Establishment of a novel triple-transgenic mouse: conditionally and liver-specifically expressing hepatitis C virus NS3/4A protease.Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products.Opening the door for hepatitis C virus infection in genetically humanized mice.Adapted HCV JFH1 variant is capable of accommodating a large foreign gene insert and allows lower level HCV replication and viral productionInteraction of Hepatitis C Viral Proteins with Cellular Oncoproteins in the Induction of Liver Cancer
P2860
Q24606893-3E550633-A9D3-467C-A0E6-CB67DD220EEEQ24634479-9B3212E5-2E84-4581-AB49-1A8E3046F25DQ26991855-292BF386-A637-4FCB-8FEF-49723AEE4E08Q27469084-F64794E4-A32A-46C9-B6AD-63C8902373F4Q28115899-29BA8952-4AF8-4622-B811-F483F806C10BQ28482493-15228C28-A1E7-45AC-857C-2C3B86A7BBA6Q28485227-61E917A4-8F80-4DF2-B807-150D6B8D4CD7Q28539751-5739D696-2CDC-4F29-96E8-1B7A2EF1B954Q33837260-2DF653D3-A526-4100-894E-B00C90662D76Q34175159-1A60FBB3-52DA-4652-A845-93D27CB730ACQ34427768-E5643543-37BD-4260-AC84-0F5099F56F13Q34936072-324FD7C4-F4D3-4BBD-B78F-980CEE805FE9Q35488854-86973F71-2BDE-4EAF-90A9-8370007C284DQ35754904-1E50D5C7-57BA-4307-BE07-13251C07865FQ35832272-EA226246-A9C5-4BD9-BAF0-DCF6EB0874D2Q35943663-B8C8480B-2601-4186-B70B-DC97FC629B7EQ36607790-921822F8-DBC9-4C1C-B335-E68D27FB3132Q36607822-F9A5D4C4-80B9-46C7-97FB-8CE6D8CC9C0EQ36839847-761E3138-12F6-481D-8DD4-21970D3320A2Q37347377-95CF31D6-4BFA-4AB7-9956-946226CB9738Q38113079-6D381486-8A31-4BF1-9858-649491FD07B5Q38190014-8B5EA9E2-0E30-49AD-8024-A46C12AEE1D9Q38410753-A364F48D-987F-4A79-A5EB-A04029B23E8FQ38695792-7DCDCE8B-0849-4ECC-816A-013AC32DD03DQ38778496-8849678D-7BC2-47BA-AD07-C4A5C9C9EF0BQ38836459-239EA786-71A0-4693-85AD-00D121BB0171Q39034736-01749E46-26D1-4D60-B928-98ADE080FCB3Q39084971-7FCA86D6-7206-4367-BBC0-7BD8240E48F3Q39157496-B78D26F3-87DD-46A1-BA15-0D9E5ECB4712Q39246243-5AC0BC0C-5F60-41D1-B39C-17721977A14CQ41748304-991735C5-5B83-431A-AFE0-10810B1516EAQ42983405-9173E884-0A66-44AD-B5CA-C6227F2AA78AQ45362055-A7EAF8D8-9382-4F73-B990-0317DBD126B8Q56397942-5D5773E1-E83D-4CF7-9A81-F37A46DC367BQ59047334-8D275AA4-EA66-400D-8945-983832E9FE10
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Turning hepatitis C into a real virus.
@en
Turning hepatitis C into a real virus.
@nl
type
label
Turning hepatitis C into a real virus.
@en
Turning hepatitis C into a real virus.
@nl
prefLabel
Turning hepatitis C into a real virus.
@en
Turning hepatitis C into a real virus.
@nl
P1476
Turning hepatitis C into a real virus.
@en
P2093
Catherine L Murray
Charles M Rice
P304
P356
10.1146/ANNUREV-MICRO-090110-102954
P577
2011-01-01T00:00:00Z